Meditor Group’s Celldex Therapeutics CLDX Stock Holding History

Meditor Group’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-196,846	Closed	-$2.56M	–	6
2020 Q2	$2.56M	Sell	196,846 -224,000	-53%	-$993K	0.54%	6
2020 Q1	$563K	Hold	420,846	–	–	0.19%	6
2019 Q4	$708K	Hold	420,846	–	–	0.2%	6
2019 Q3	$896K	Hold	420,846	–	–	0.22%	9
2019 Q2	$1.13M	Hold	420,846	–	–	0.23%	9
2019 Q1	$2.07M	Sell	420,846 -1	-0%	-$5	0.39%	9
2018 Q4	$1.25M	Hold	420,847	–	–	0.26%	6
2018 Q3	$2.85M	Hold	420,847	–	–	0.61%	6
2018 Q2	$3.18M	Hold	420,847	–	–	0.62%	6
2018 Q1	$14.7M	Hold	420,847	–	–	2.31%	4
2017 Q4	$17.9M	Hold	420,847	–	–	2.31%	4
2017 Q3	$18.1M	Buy	420,847 +34,180	+9%	+$1.28M	2.74%	4
2017 Q2	$14.3M	Buy	386,667 +110,274	+40%	+$4.88M	2.16%	8
2017 Q1	$15M	Buy	+276,393	New	+$14.4M	2.68%	7

Other funds holding CLDX

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Meditor Group's CLDX Position: Q3 2020 in Review

Meditor Group sold out of Celldex Therapeutics (CLDX) in Q3 2020, closing a stake of 196,846 shares — an estimated $2.56M sold.

Meditor Group first reported a position in CLDX in Q1 2017 and held it in 14 quarters. The position peaked at $18.1M in Q3 2017. 91 funds tracked by Wall St. Rank hold CLDX as of Q3 2020.

Meditor Group reported no remaining Celldex Therapeutics position as of Q3 2020 after selling out during the quarter.
Meditor Group sold 196,846 Celldex Therapeutics shares in Q3 2020, an estimated $2.56M.
Meditor Group first reported a position in Celldex Therapeutics in Q1 2017 and held it in 14 quarters.
Meditor Group's Celldex Therapeutics position peaked at $18.1M in Q3 2017.
91 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2020.

Based on Meditor Group's 13F filing for Q3 2020, filed 19 Oct 2020.